BRCA1 and BRCA2 identified (1994-1995)
Two genes behind inherited breast and ovarian cancer were cloned within a year of each other, turning a family pattern into a testable mutation. Commercial testing arrived quickly, initially through one company's patents.
Carriers could learn their risk and choose earlier screening or preventive surgery.
BRCA testing became routine, and drugs that exploit the same broken DNA-repair pathway, including PARP inhibitors, were approved for carriers.
CDK12 also codes for a DNA-repair protein. This is the template the new finding is trying to follow: inherited variant, then panel, then possibly a drug that targets the defect.
